News & Blog

Keep up to date with our latest product news, information and events. We’ll also share our expert
insights into the world of genomic healthcare.

Introducing Whole Genome Sequencing service

Government regulations, recently announced in the UK, now require Whole Genome Sequencing to be carried out as part of the minimum standards for COVID-19 tests for people arriving in England. In order to support SARS-CoV-2 testing laboratories, we have introduced a Whole Genome Sequencing service.
Read More
COVID-19 Whole Genome Sequencing Service

What’s in a name?

When Chris Sale and Lee Silcock founded Nonacus in 2015 they had one singular purpose- to develop non-invasive DNA tests that would change the way genomic diagnostics was done. Choosing a name that would reflect this mission wasn't easy. Find out why they went with 'Nonacus'.
Read More

Delivering the potential of cancer genomics to patients

This week Nonacus Ltd announced a partnership with Dante Labs and Cambridge Cancer Genomics which aims to build the most comprehensive and patient-centric tumour profiling service enabling improved cancer patient management, treatment and monitoring.
Read More

Nonacus wins Government grant to validate rapid sequencing based surveillance testing for COVID-19.

Nonacus was recently awarded an Innovate UK grant to validate novel, rapid surveillance testing for respiratory viral genomes using nanopore sequencing. This method will provide more comprehensive information about the SARS-CoV-2 genome and with a respiratory viral panel in the pipeline, will provide surveillance of other respiratory diseases too.
Read More

No Gluten Required

Nonacus scientists, together with researchers at the University of Cambridge, are working on the development of a novel, non-invasive test for coeliac disease that works even if the patient is already on a gluten-free diet.
Read More
Gluten free

UK firm develops coronavirus spit test which could be done at home

Suspected coronavirus patients could be asked to spit into a tube and post the sample to a lab, under plans for a new test being developed by a British firm. Read the interview with Nonacus Ltd in the Sunday Telegraph on how a partnership with Chronomics has led to the development of a spit test for COVID-19.
Read More

Covid-19. Can we help?

The impact of the coronavirus is being felt right across the UK and I hope that you, your family and your friends remain safe and well. With yesterday’s announcement from the government, we know that this impact will be wide ranging and may be having a knock on effect on your laboratory. We are hearing of laboratory closures during the self-isolation period and labs operating with a skeleton staff, all of which puts pressure on laboratory services.
Read More

Nonacus introduces ExomeCG product to simplify molecular and cytogenomics data generation and interpretation

Nonacus Ltd, a UK based precision medicine company and manufacturer of ultra-sensitive next-generation sequencing (NGS) products, has announced the launch of ExomeCG, a new product to simplify the generation and interpretation of molecular and cytogenomic data. The new product has been co-developed with digital health technology company, Congenica Ltd, which specialises in software solutions that enable accelerated interpretation of complex genomic data to improve disease diagnosis.
Read More
Exome sequencing for cytogeneticists

New QA / QC Production Scientist Role at Nonacus

We are excited to announce that Nonacus are recruiting! Following the successful launch of our Cell3TM DNA product range we are now growing the team and are seeking a highly motivated experienced Quality Assurance (QA) / Quality Control (QC) Production Scientist to join our team. The full job description and details on how to apply...
Read More